Medications for alcohol‐use disorder and follow‐up after hospitalization for alcohol withdrawal: A multicenter study
Allaudeen N, Akwe J, Arundel C, Boggan J, Caldwell P, Cornia P, Cyr J, Ehlers E, Elzweig J, Godwin P, Gordon K, Guidry M, Gutierrez J, Heppe D, Hoegh M, Jagannath A, Kaboli P, Krug M, Laudate J, Mitchell C, Pescetto M, Rodwin B, Ronan M, Rose R, Shah M, Smeraglio A, Trubitt M, Tuck M, Vargas J, Yarbrough P, Gunderson C. Medications for alcohol‐use disorder and follow‐up after hospitalization for alcohol withdrawal: A multicenter study. Journal Of Hospital Medicine 2024 PMID: 39031461, DOI: 10.1002/jhm.13458.Peer-Reviewed Original ResearchAlcohol-use disordersResidential treatment programAlcohol withdrawalFollow-up appointmentsImprove abstinenceAll-cause 30-day readmissionFollow-upTreatment programsReturn to heavy drinkingAssociated with improved outcomesRetrospective cohort studyOutpatient follow-upEffects of medicationAssociated with readmissionTime of dischargeVeterans Health Administration hospitalsAssociated with decreased readmissionMulticenter studyAcute care hospitalsAssociated with reduced 30-day readmissionsResidential programsPrescription of medicationsAbstinenceCohort studyHeavy drinkingContribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox model